Alzheimer’s Disease: Current and Future Treatments. A Review by Chou, Evelyn
The International Journal of Medical Students Int J Med Students   •   2014  Mar-Jun  |  Vol  2  |  Issue 256
IJMS
International Journal of
Medical Students Review
Alzheimer’s Disease: Current and Future Treatments. A 
Review
Evelyn Chou1
Abstract
Alzheimer’s disease (AD) is a currently incurable neurodegenerative disorder whose treatment poses a big challenge. Proposed causes of 
AD include the cholinergic, amyloid and tau hypotheses. Current therapeutic treatments have been aimed at dealing with the neurotrans-
mitter imbalance. These include cholinesterase inhibitors and N-Methyl-D-aspartate (NMDA) antagonists. However, current therapeutics 
have been unable to halt AD progression. Much research has gone into the development of disease-modifying drugs to interfere with the 
course of the disease. Approaches include secretase inhibition and immunotherapy aimed at reducing plaque deposition. However, these 
have not been successful in curing AD as yet. It is believed that the main reason why therapeutics have failed to work is that treatment 
begins too late in the course of the disease. The future of AD treatment thus appears to lie with prevention rather than cure. In this article, 
current therapeutics and, from there, the future of AD treatment are discussed.
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Introduction
The most common form of dementia is Alzheimer’s disease 
(AD). It is a degenerative and currently incurable terminal di-
sease, affecting about 75% of the 35 million people worldwide 
suffering from dementia. It is predicted that the prevalence of 
AD will double every 20 years, meaning an estimated 115 mi-
llion individuals may be suffering from AD by 2050.1 AD is thus 
becoming increasingly recognized as a major cause of medical 
and social burdens in the elderly population worldwide.2 In its 
preclinical stages, AD cannot be diagnosed, while its clinical 
stages are characterized by impairment of cognitive functions 
(i.e. recent memory, language difficulties, spatial disorientation 
and visual agnosia), with behavioural disturbances significant 
enough to compromise activities of daily living (ADLs). Life ex-
pectancy is reduced, with patients generally living up to 5-8 
years following diagnosis.3
Currently, no drugs are available to halt the progression of neu-
rodegeneration in AD; the nature of AD treatment is symptoma-
tic.2 For instance, cholinesterase inhibitors (CIs) that promote 
cholinergic neurotransmission are used in mild to moderate 
cases of AD. Memantine, an N-methyl-D-aspartate (NMDA) re-
ceptor antagonist, is used in moderate to severe cases to pre-
vent excitotoxicity,4 and antipsychotics and antidepressants are 
used in the treatment of neuropsychiatric symptoms.5
The future of treatment of AD lies in the targeting of neuritic 
plaques (NPs) and neurofibrillary tangles (NFTs), which has the 
potential to delay neurodegeneration.6
The daunting statistics and the impacts that AD has on suffe-
rers, caregivers and the society make it exceptionally vital that 
we review how AD is currently being treated and how this is 
likely to change in the near future with the possible develop-
ment of disease modifying treatments.
Search Strategy and Selection Criteria
The papers for this review article were identified by compu-
terized advanced searches in Pubmed database and Google 
Scholar using the keywords ‘Alzheimer’s’, ‘beta-secretase’ and 
‘gamma-secretase’. These papers included meta-analyses, ori-
ginal research articles, review articles and clinical trials.  In-
formation was also obtained from textbooks and Alzheimer’s 
disease forums. This review follows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Sta-
tement.7
Clinical Features 
The progression of AD can be divided into a series of stages: 
pre-dementia, mild, moderate and severe. 
The pre-dementia stage is often unreliably distinguished from 
normal aging or stress-related issues.3,8 One of the first signs 
is the deterioration of episodic memory. No decline in sensory 
or motor performance occurs at this stage, and other aspects 
such as executive, verbal and visuospatial functions are slight-
ly impaired at most. An individual remains independent and is 
not diagnosed as suffering from AD.8 
During mild stages of AD, increased memory loss affects re-
cent declarative memory more profoundly than other capaci-
ties, such as short-term, declarative and implicit memories.3 
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Motor function remains normal, and sensory performance is 
not impaired extensively. However, some visual, auditory and 
olfactory functions may be affected.8 Communication begins 
to decline as patients find themselves unable to recall certain 
words. The individual may be able to remain independent, but 
not without some assistance.3,9
Recent memory continues to deteriorate in the moderate stage. 
Due to an inability to create new memories, AD patients seem 
to live in the past.9 Patients are still able to manage basic ADLs, 
but help is required in certain areas such as grooming and 
dressing.3,9 Insight into their disease is commonly lost by this 
stage, with patients becoming delusional. A longitudinal study 
conducted in 1993 showed that it is at this stage that cognitive 
decline, aggression, depression and incontinence in patients 
become predictive factors for placement in nursing homes.10
In the severe stage, even early memories can be lost. Basic 
ADLs are now affected, declining gradually. Communication de-
teriorates further to single words or phrases, and language is 
thus significantly impaired.3,9 Behavioural disturbances occur, 
causing disruptions to caregivers.3,11 The most common cause 
of death in AD patients is pneumonia,12 followed by myocardial 
infarction (MI) and septicaemia.3  
Risk Factors 
Inheritance of certain genes is a risk factor for AD, with both 
familial and sporadic cases occurring. In sporadic AD, which is 
the more common form, there is a link with the apolipoprotein 
?4 (APOE4) allele, with the risk being greater in homozygotic si-
tuations.1,13 It has been shown that transgenic mice expressing 
either mouse or human apoE develop neuritic plaques (NPs) 
associated with neuritic degeneration due to fibrillar amyloid-ß 
deposits. n contrast, in apoE negative mice, no neuritic dege-
neration was observed despite the presence of non-fibrillary 
amyloid-ß deposits. ApoE thus appears to play a critical role in 
the progression of NPs and degeneration.14
  
Environmental factors also contribute to the development of 
sporadic AD.15 Familial AD, on the other hand, has been asso-
ciated with mutations in presenilin 1 (PSEN1) and presenilin 2 
(PSEN2), as well as the amyloid precursor protein (APP) gene, 
which is located on chromosome 21.1,13 Many other candidate 
polymorphic genes have been associated with increased AD 
risks, including secretase, peptidase, microtubule, cytoskele-
tal, anti-apoptotic and protease genes.1
Vascular factors seem to affect the risks of developing AD. Me-
tabolic syndrome,1 comprising hypertension, dyslipidaemia, 
obesity and diabetes mellitus, has been associated with increa-
sed risk.16 Hypertension contributes to the formation of neuritic 
plaques (NPs), neurofibrillary tangles (NFTs), and characteristic 
lesions seen in AD.17 Dyslipidaemia and diabetes mellitus are 
not only implicated in the generation of NPs, but also cause 
cerebrovascular dysfunction.18 In addition, obesity has been 
linked to cognitive decline and resistance to insulin the latter 
of which leads to hypertension, diabetes and cerebrovascular 
dysfunction.19
Psychosocial factors are also implicated in AD. With greater so-
cial, physical and mental stimulation, individuals are less likely 
to develop AD later in life. The risk of cognitive decline is higher 
in those with lower physical activity. Additionally, the protecti-
ve effect of physical activity is more prominent in apoE4 allele 
carriers. These three lifestyle factors appear to act together 
in a common pathway in their protection against dementia.1,20 
Causes
Cholinergic Hypothesis
The cholinergic hypothesis of AD came about due to the com-
bined observations of deficits in choline acetyltransferase and 
acetylcholine (ACh) and the fact that ACh is important in me-
mory and learning. It was thought that reduction in cholinergic 
neurons as well as cholinergic neurotransmission led to the 
decline in cognitive and noncognitive functions. Cholinergic 
function loss correlated to cognitive decline, but no causal re-
lationship was established.2,21 Moreover, the use of cholineste-
rase inhibitors (CIs) does not have a significant effect in more 
than half of AD patients receiving treatment, indicating the 
presence of other important processes in the progression of 
the disease.21
Amyloid Hypothesis
Amyloidosis is the abnormal deposition of amyloid proteins in 
tissues, with the altered amyloid proteins forming an insolu-
ble ß-pleated sheet. Reduced tissue and cellular clearance is 
observed in amyloid protein deposits. The membrane protein 
amyloid-ß precursor protein (APP) is proteolysed to form Aß, 
and it is the amyloid form of Aß that makes up the amyloid 
plaques (neuritic plaques) found in the brains of AD sufferers.6
According to the amyloid hypothesis, the basis of AD is the pre-
sence of Aß production in the brain.2 Evidence for the amyloid 
hypothesis was compelling, as gene mutations encoding the 
amyloid-ß precursor protein (APP) was found to cause familial 
AD, with sites of major mutations found in ? secretase and 
APP.6 Aß is derived from APP by proteolysis in the amyloidoge-
nic pathway, mediated by ß secretase (BACE1) and ? secretase, 
in the extracellular and transmembrane region, respectively. 
Cleavage by ß-secretase produces APPsß and C99. C99 is fur-
ther cleaved by ? secretase to form either Aß1-40 or the more 
hydrophobic, aggregation-prone Aß1-42.22
Aß40 is more predominant in cerebral vasculature.2 APP can 
also be cleaved by ? secretase in the non-amyloidogenic pa-
thway, producing APPS? and C83. Further evidence came from 
an experiment in the 1990s whereby transgenic mice expres-
sing three different isoforms of mutant APP were found to have 
characteristic AD neuropathologies.23
Despite widespread support of Aß fibrils being the main cause 
of pathology seen in AD, it was suggested that oligomerization 
of Aß1-42 plays a more important role. Oligomerization of Aß1-
42 produces soluble Aß oligomers which are known as Aß-deri-
ved diffusible ligands (ADDLs). Experiments showed that these 
ADDLs are potentially more toxic than Aß fibrils as they target 
synaptic spines and disrupt synaptic plasticity, thus affecting 
cognitive function. Their toxicity lies in toxin receptors on cell 
surfaces and in Fyn, a tyrosine kinase receptor overexpressed 
in AD (Figure 1).24,25
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Tau Hypothesis
The Tau hypothesis revolves around the presence of neuro-
fibrillary tangles (NFTs) in AD. As a result of increased phos-
phorylation of Tau (originally bound to microtubules), there 
is an increase in free tau accompanied by loss of functioning 
microtubules.26 Phosphorylated Tau are subunits of paired he-
lical filaments (PHFs), which form NFTs. The impaired microtu-
bules affect axonal transport of proteins and eventually cause 
neuronal death.27
Neuropathology 
The degeneration of neurons and synapses, declining choliner-
gic function, characteristic neuropathologic lesions of neuritic 
plaques (NPs) and neurofibrillary tangles (NFTs) all contribute 
to cognitive decline.28 The neocortex and hippocampus, which 
are the regions of higher function, are most affected by the-
se lesions.21 NPs consist of aggregations of amyloid-ß peptide, 
while NFTs are located within neurons and their projections 
and are composed of filamentous hyperphosphorylated tau. 
The distinction between NPs and NFTs being causative or mere 
markers of AD and the chronological order in which the patho-
logies appear are important to the understanding of AD patho-
logy.6 A study carried out to determine the role of NPs and NFTs 
in AD established that NP deposition occurs in early stages of 
the disease, but does not correlate with progression of illness 
once clinical stages have been established, whereas NFTs seem 
to correlate to decline in cognitive function in later stages.28
Current Symptomatic Treatments
It is through the understanding of the disease processes that 
underlie AD that targets can be ascertained and treatments 
developed.
Cholinesterase Inhibitors
Cholinesterase inhibitors (CI) aim to increase acetylcholine 
availability in synaptic neurotransmission in order to treat me-
mory disturbances. Currently, three CIs are being used as the 
first-line treatment in mild to moderate AD: donepezil, rivastig-
mine and galantamine.2 While donepezil and rivastigmine are 
both selective inhibitors, galantamine inhibits both ACh and 
butyrylcholinesterase. A meta-analysis collaborating 13 rando-
mized, double-blind trials that were designed to evaluate the 
effectiveness and safety of CIs showed no improvement in ADL 
and behaviour. In addition, donepezil and rivastigmine showed 
no significant difference in their impact on cognitive functions, 
ADLs and behaviour. Overall, similar benefits were observed 
across all three drugs.29 It is known that CIs are unable to halt 
disease progression, but they have been found to have effects 
for a substantial period of time. As seen in a randomized dou-
ble-blind trial, patients undergoing long-term treatment with 
donepezil showed no beneficial loss for up to two years.30 
In addition, there may be some added benefits to increased do-
ses of CIs given. In a randomized, double-blind, parallel-group, 
48-week study conducted to determine the efficacy and safety 
of a rivastigmine patch of a higher dose, deterioration of ADLs 
was significantly reduced and Alzheimer’s Disease Assessment 
Scale-cognitive subscale (ADAS-cog) was improved in patients 
treated with higher doses.31 Side effects as a result of CIs are 
minimal and are usually limited to gastrointestinal symptoms 
such as diarrhea, nausea and vomiting.13
NMDA Receptor Antagonists
Memantine is a non-competitive NMDA receptor antagonist 
effective in the treatment of moderate-to-severe AD. The modu-
Figure 1. The Amyloid Hypothesis: Amyloidogenic and Non-amyloidogenic Pathways.
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lation of NMDA receptors results in reduced glutamate-induced 
excitotoxicity. Its benefits were proven in a 28-week, double 
blind, parallel-group study which showed that treatment signi-
ficantly reduced deterioration in patients. Most adverse reac-
tions to the drug were not severe and were considered to be 
unrelated to the drug. The positive effect on cognitive function 
translates to behavioural improvements: patients were less agi-
tated and required less assistance from caregivers.32 Improve-
ment of the behavioural and psychological symptoms related 
to dementia (BPSD) was also highlighted by a meta-analysis of 
6 studies involving memantine treatment.33
Antidepressants and Antipsychotics
BPSD is a common occurrence in AD and a major source of 
burden on caregivers. CIs and memantine help to control these 
symptoms to a certain extent, but as patients continue to dete-
riorate, control by these drugs becomes insufficient.2
Depression is very common, especially in the early and late 
courses of the disease. Antidepressants such as: selective 
serotonin reuptake inhibitors (SSRI: citalopram, fluoxetine, 
paroxetine, sertraline, trazodone), tricyclic agents and combi-
ned serotonergic and noradrenergic inhibitors may be used to 
counter this.2,34 Discontinuation of antidepressants in demen-
ted patients in a double blinded, randomized, parallel-group 
placebo controlled trial showed significant increases in depres-
sion when compared to those who continued treatment. These 
results are indicative of the beneficial effects of antidepres-
sants.34 
Atypical antipsychotics used in AD include olanzapine, quetia-
pine and risperidone, which are used to treat psychosis and 
agitation. However, the use of such drugs appears to be contro-
versial, with patients showing significant declines in cognitive 
function with antipsychotic drugs administration when compa-
red to patients receiving the placebo.35
Disease-Modifying Treatments
While symptomatic treatments have proven helpful, it is the 
finding of a cure that is most vital. Since the amyloid hypo-
thesis indicates that Aß generation and deposition from ove-
rexpressed APP cleavage make up the fundamental basis of 
AD, interest centers on anti-amyloid therapies. These therapies 
result in decreased production of Aß, increased clearance of Aß 
and the prevention of Aß aggregation into amyloid plaques.6,36 
Immunotherapy has also been an area of interest as it targets 
the clearing of Aß peptides, which can either directly or indi-
rectly impact cognitive decline.37 
Focusing on decreasing Aß generation, several methods can be 
employed to achieve this, mainly by targeting the amyloidoge-
nic and nonamyloidogenic pathways. ß and ? secretases both 
compete for APP, with ß- and ?-secretase processing ultimate-
ly resulting in amyloid deposition and ?-secretase generating 
soluble APPs?.2 Inhibiting ß- and ?-secretases while simulta-
neously potentiating ?-secretase action would thus reduce Aß 
generation and deposition overall.
Decreasing Aß Generation
ß-Secretase Inhibitors 
The cloning of ß-secretase has allowed for the investigation of 
its structural and catalytic properties.38 Development of clinica-
lly effective inhibitors depends greatly on this detailed knowle-
Figure 2. Possible Therapeutic Targets in Anti-amyloid Therapies
The International Journal of Medical Students Int J Med Students   •   2014  Mar-Jun  |  Vol  2  |  Issue 260
IJMS
International Journal of
Medical Students Review
dge of its structure. ß-secretase is a rate-limiting transmem-
brane aspartyl protease beta-site APP-cleaving enzyme (BACE1) 
involved in the first proteolytic step of the amyloidogenic pa-
thway of Aß generation. BACE1-deficient mice were used to de-
termine the role of ß-secretase. In mice with BACE1-/- neurons, 
generation of Aß40 and 42 was eradicated, thus confirming the 
role of BACE1 in the amyloidogenic pathway.39 From this, it can 
be inferred that inhibition of BACE1 activity would be able to 
reduce Aß levels and ultimately reduce neuritic plaques. Thus, 
it has become a primary therapeutic target.
 
The close resemblance of ß-secretase’s catalytic apparatus to 
other aspartyl protease targets such as HIV protease has con-
tributed to the development of its inhibitors.39 However, the 
secretase’s hydrophilic, long and shallow active site presents 
some problems to the development of its inhibitors. An effecti-
ve inhibitor would need to be able to penetrate the blood-bra-
in-barrier (BBB) and the cell membrane of neurons. This has 
made the discovery of small yet potent inhibitors more diffi-
cult.36 Another challenge is that ß-secretase inhibitors act as 
substrates for P-glycoprotein that transports them out of the 
brain. Efforts have been made to overcome this through the 
design of inhibitors with higher selectivity for BACE1 over me-
mapsin 1 (BACE2) and cathepsin D (cathD).2,39 The low number 
of drugs reaching clinical trials reflects the difficulty of these 
challenges faced (Figure 2).
The earliest BACE1 inhibitors were peptidic, large, polar and 
clinically ineffective. These have been progressively improved 
and they have been made less peptidic. The first orally bioa-
vailable drug-like non-peptidic BACE1-inhibitor LY28113776 was 
found to significantly lower Aß protein in animal models. Heal-
thy volunteers later treated with the compound also demons-
trated this decrease in Aß levels. Its safety, tolerability and 
efficacy were determined in a double blind, placebo controlled 
study in which subjects were assigned either the active drug 
or a placebo and participated in CSF and plasma sampling. 
The drug was discontinued due to its pathological effect on 
accumulations of autofluoroscent material within the retinal 
epithelium, causing them to be enlarged. Although the drug did 
not go on to enter the later clinical trial stages, data recorded 
nevertheless provides support for BACE1 as a target for BACE1 
inhibitors.40 
Despite support for BACE1 inhibitors, certain concerns were yet 
to be dealt with. In particular, it was not known whether BACE1 
played other important physiological roles apart from being 
involved in the amyloidogenic pathway.40 In a 2006 study, it was 
discovered that BACE1 is involved in the myelination process of 
peripheral and central nerves. In BACE1-null mice, hypomyeli-
nation occurred. This hypomyelination was thought to be due 
to the role of BACE1 in the cleavage of neureguin-1 type III, a 
myelination initiator. At this point, it was still unclear whether 
neuroglenin-1 cleavage is required for myelin sheath matura-
tion, which would make BACE1 inhibitors potentially dange-
rous.41 However, it was later found that neuroglenin1 signalling 
is in part independent of BACE1 function. Even though BACE1’s 
processing of the gene does produce a myelin-inducing signal, 
this signal is not essential for myelination stimulation.42
The first ß-secretase inhibitor to enter Phase I clinical trials was 
announced in 2008.2 This compound, CTS-21166, developed by 
CoMentis, was able to significantly lower Aß levels. It was not 
only potent (1.2-3.6 nm), but also selective.  In cellular assays 
performed, CTS-21166 did not bind to 60 other enzymes.38,40 
This was an achievement, as non-specific binding was one of 
the major issues in developing a clinically effective ß-secretase 
inhibitor. It also displayed desirable brain penetration, another 
problem associated with the development of other inhibitors 
(Strobel G. Keystone Drug News: CoMentis BACE inhibitor debut. 
http://www.alzforum.org/new/detail.asp?id=1790. Cited  2013 
Sep 30). The injection of CTS-21166 into transgenic mice resul-
ted in reduction of Aß 40 and 42 by an average of 36.5% as well 
as reduction in amyloid plaques in hippocampal and cortical 
areas by about 40%. Using this knowledge, the compound was 
then tested on healthy male volunteers for its tolerability and 
safety in 6 volunteers, with a range of doses (7.5-225 mg) given 
intravenously. Results were positive, showing good tolerability 
over the range of doses administered and slow drug clearance 
(Strobel G. Keystone Drug News: CoMentis BACE inhibitor de-
but). Significant plasma Aß inhibition continued for up to 72 
hours, with recovery to normal levels by 144 hours after the 
inhibitor was administered.39 Later phase clinical trials have yet 
to be published.  
?-Secretase Inhibition 
?-secretase inhibition is perhaps the most widely and frequent-
ly studied mechanism to reduce Aß. It is involved in the second 
step of the amyloidogenic pathway and is thus crucial in Aß 
generation. Another product derived from ?-secretase cleavage 
is the amyloid intracellular domain (AICD), which may have 
a role in gene expression downstream.6 ?-secretase is an in-
tra-membrane cleaving protease, consisting of 4 components: 
presinilin (PS), nicastrin (NCT), presenilin enhancer (Pen2) and 
anterior pharynx defective (Aph1). These 4 components were 
thought to be essential for the activity of ?-secretase, and the 
loss of any of the proteins appeared to abolish the activity of 
?-secretase. However, in NCT knock-out mice, it was observed 
that a complex of PS1, Pen2 and Aph1a was able to function 
as a ?-secretase inhibitor, which indicated that NCT is not re-
quired for substrate recognition in ?-secretase. Instead, it is 
thought to have a role in the stabilization of the enzyme. This 
makes it much more complex than ß-secretases.6, 43 Even thou-
gh NCT may not be the most important component, ?-secretase 
activity is PS dependent. It was the combined knowledge of 
mutations in PS1 and PS2 resulting in early-onset of AD and 
PS mutations also causing increased levels of Aß that led to 
the belief that PS has a direct impact in ?-secretase mediated 
cleavage of APP.44 In an investigation of PS-1 deficient mouse 
embryos, the cleavage of APP by ?-secretase was prevented, 
causing Aß levels to be significantly reduced, whereas cleavage 
by ß- and ?-secretase was unaffected.45 This thus confirmed 
the function of presenilin in ?-secretase.
Despite ?-secretases’ complexity, the development of ?-secre-
tase inhibitors has been easier than the development of ß-se-
cretase inhibitors. This is due to the hydrophobicity of its  ac-
tive site. Inhibitors developed were hydrophobic, which aided 
its permeability, and penetrating the BBB and neuronal mem-
branes was less of a problem.6 However, its development was 
not without challenges. The most serious concern faced was 
that ?-secretase had other physiological roles in development 
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via Notch signalling regulation.  Normally, Notch is cleaved in 
the Golgi apparatus to produce mature Notch1 protein. Notch-1 
undergoes further cleavage to release the Notch intracellular 
domain (NICD). NICD in turn modifies the transcription of tar-
get genes within the nucleus. In PS1 knock-out cells, it was 
observed that PS1 is vital in the cleavage of APP and Notch.46 
Hence, the use of ?-secretases in the treatment of AD can be 
expected to cause gastrointestinal toxicity, immunosuppression 
and anaemia due to the role of Notch-1 in haematopoiesis. 
PS is also involved in several other processes, such as the 
cellular trafficking of proteins. The knock out of PS would lead 
to the accumulation of protein fragments within the cell due 
to interrupted transport between subcellular compartments. It 
has also been suggested that PS plays a role in homeosta-
sis of Ca2+.47 Efforts to overcome these challenges come from 
the development of selective ?-secretase inhibitors that target 
cleavage of APP only.
Notch-sparing ?-secretase inhibitors have also been developed, 
and these are able to reduce APP proteolysis in the amyloidoge-
nic pathway, thus decreasing Aß, while preventing the cleavage 
of Notch.47 One of the first compounds with this property was 
STI571 (Gleevec), an abl kinase inhibitor. STI571 was found to be 
able to reduce Aß production, albeit weakly, while at the same 
time did so without causing cleavage of Notch. These agents 
formed the basis of development of a number of more potent 
selective inhibitors, and several of such inhibitors have been 
reported to enter clinical trials.47,48 
LY-450139 (Semagacestat), a selective ?-secretase inhibitor that 
is able to reduce Aß production, has been the most widely 
studied. LY-450139 resulted in dose-dependent decrease in Aß 
concentrations over a period of 6 hours post-administration, 
with maximum reduction of 40% relative to the baseline con-
centration.49 This correlated with the fact that semagacestat is 
absorbed rapidly from the gut, reaching its peak 1.5 hours after 
administration and the fact that it is mainly excreted renally. In 
its phase I clinical trial, manageable adverse events were repor-
ted. In the Phase II 14-week study performed in 51 mild-to-mo-
derate cases of AD, semagacestat was shown to be safe and 
tolerable.50,51 However, during its Phase III trial in 2010, the drug 
was discontinued due to its detrimental effects on cognitive 
function of patients receiving it compared to those receiving 
the placebo. Semagacestat also appeared to be associated with 
increased risks of skin cancer. Such harmful effects were thou-
ght to be due to the involvement of the inhibitor with Notch 
cleavage and CTFß, a neurotoxic precursor of Aß (AlzForum. 
Drugs in clinical trials. http://www.alzforum.org/drg/drc/detail.
asp?id=108. Accessed: 2 Apr 2013).2 Setbacks have also been 
faced in other trials, as seen in Phase III clinical trials of taren-
flubril. These trials aimed to determine the efficacy, safety, and 
tolerability of the drug in the treatment of mild-to-moderate AD 
patients. However, results failed to show any benefit from ta-
renglubril in the cognitive function of patients. Possible reasons 
for this lack of success include insufficient doses and its low 
penetration across BBB.52
BMS-708163 (Avagacestat) is another example of a ?-secretase 
inhibitor. Its phase I clinical trial assessed its tolerability, safety 
and pharmacokinetic properties in young, healthy male volun-
teers. It reached its peak concentrations rapidly, in about 1.5 
hours, with a plasma half-life of about 33 to 34 hours. There 
was a dose proportional increase in plasma concentration wi-
thin the range of 0.3-800 mg of the drug.  Avagacestat was able 
to reduce Aß by up to 88% 1 hour post-administration. Some 
minor side effects included nausea, dizziness and headaches, 
with no serious side effects or deaths reported. This phase I 
clinical trial thus demonstrated Avegacestat’s tolerability for 
up to 800 mg dosage, and its suitability for progression into 
larger clinical studies.53 In a phase II clinical trial, 209 patients 
with mild-to-moderate AD were randomized to receive either 
the active compound or a placebo. The phase II clinical trial 
established that daily doses of 25 and 50 mg were indeed we-
ll-tolerated, whereas 100 and 125 mg doses were not as well 
tolerated and had a tendency to cause worsening of cognitive 
function and GI disturbances related to Notch involvement.54 
These clinical trials have so far established an acceptable dose 
range for future studies of Avagacestat.
 
Conclusion
Taking into account the amount of research that has gone 
into developing secretase inhibitors, the outcome has not 
been desirable. The trials so far have come up empty handed, 
showing no therapeutic improvements in AD patients.  As a re-
sult, there has been reasonable concern that anti-amyloid the-
rapies may have no therapeutic effect in patients, which would 
mean decades of wasted research and possibly the targeting of 
the wrong compounds. Hope that anti-amyloid therapies would 
have a significant positive impact on AD patients is slowly dis-
sipating. This doubt is further enhanced by the immunization 
of patients with full length Aß-peptides in an attempt to clear 
the NPs from the brain. Previously, it was unknown whether 
active immunization of Aß was able to benefit patients. Thus, a 
trial was carried out to determine its beneficial effects. In this 
Phase I, randomized, placebo-controlled follow up on the long 
term effects of Aß immunization (AN1792), data obtained indi-
cated that immunization was indeed able to significantly re-
duce Aß deposition in the AD brain, in comparison to patients 
receiving the placebo. Disappointingly, despite the pathological 
improvements observed, the drug failed to produce results of 
cognitive improvement in these patients. On top of this, some 
patients even progressed to clinically severe dementia.55 What 
these results imply is that the removal of NPs alone may be 
insufficient in the disease-modifying treatment of AD. Perhaps 
challenges against the amyloid hypothesis are reasonable, and 
other factors such as tau hyperphosphorylation's contribution 
to AD should be re-examined in greater detail. 
However, despite the disappointing lack of improvement in 
patients with Aß generation and deposition, there still is the 
possibility that these anti-amyloid strategies hold the potential 
to cure AD. Concluding that anti-amyloid strategies are futile at 
this point in time would be rash. 
First of all, anti-amyloid therapies were indeed successful, as 
they were able to reduce NPs. Secondly, Aß  deposition for-
ming NPs was shown to be one of the earliest signs of AD, 
whereas cognitive decline correlated with NFT deposits.28 NPs 
were thought to be the earliest signs of AD, as individuals with 
trisomy 21 on which the gene for APP is located developed AD 
much earlier.56 Such observations were also made in individuals 
with familial AD. The initial Aß deposition is thought to set off 
The International Journal of Medical Students Int J Med Students   •   2014  Mar-Jun  |  Vol  2  |  Issue 262
IJMS
International Journal of
Medical Students Review
References
1. Povova J, Ambroz P, Bar M, Pavukova V, Sery O, Tomaskova H, et al. Epide-
miological of and risk factors for Alzheimer’s disease: A review. Biomed Pap 
Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):108-14. 
2. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Al-
zheimer’s disease. Ther Adv Neurol Disord. 2013 Jan;6(1):19-33.
3. Förstl H, Kurz A. Clinical features of Alzheimer’s disease. EEur Arch Psy-
chiatry Clin Neurosci. 1999;249(6):288-90.
4. Lukiw WJ. Amyloid beta (Aß) peptide modulators and other current treat-
ment strategies for Alzheimer’s disease (AD). Expert Opin Emerg Drugs. 2012 
Mar 23. [Epub ahead of print]
5. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people 
with dementia. CNS Drugs. 2010 Sep;24(9):729-39. 
6. Martâinez A. Emerging drugs and targets for Alzheimer’s disease; Volume 
1: Beta-Amyloid, Tau protein and glucose metabolism. Cambridge: The Royal 
Society of Chemistry; 2010.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. 
The PRISMA statement for reporting systematic reviews and meta-analyses of 
studies that evaluate health care interventions: explanation and elaboration. 
PLoS Med. 2009 Jul 21;6(7):e1000100.
8. Almkvist O. Neuropsychological features of early Alzheimer’s disease: pre-
clinical and clinical stages. Acta Neurol Scand Suppl. 1996;165:63-71. 
9. Galasko D. An integrated approach to the management of Alzheimer’s 
disease: assessing cognition, function and behaviour. Eur J Neurol. 1998 Oc-
t;5(S4):S9-17. 
10. Haupt M, Kurz A. Predictors of nursing home placement in patients with 
Alzheimer’s disease. Int J Geriatr Psychiatry. 1993 Sep;8(9):741-6. 
11. Burns A. Psychiatric phenomena in dementia of the Alzheimer type. Int 
Psychogeriatr. 1992;4 Suppl 1:43-54. 
12. Beard CM, Kokmen E, Sigler C, Smith GE, Petterson T, O'Brien PC. Cause of 
death in Alzheimer's disease. Ann Epidemiol. 1996 May;6(3):195-200. 
13. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006 
Jul 29;368(9533):387-403.
14. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, 
et al. Apoliproprotein E isoform-dependent amyloid deposition and neuritic 
degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U 
S A. 2000 Mar 14;97(6):2892-7. 
15. Piaceri I, Nacmias B, Sorbi S. Genetics of familial and sporadic Alzheimer's 
disease. Front Biosci (Elite Ed). 2013 Jan 1;5:167-77. 
16. Milinois HJ, Florentin MM, Giannopoulos S. Metabolic syndrome and 
Alzheimer’s disease: A link to a vascular hypothesis?. CNS Spectr. 2008 
Jul;13(7):606-13.
17. Skoog I, Gustafson D. Update on hypertension and Alzheimer’s disease. 
Neurol Res. 2006 Sep;28(6):605-11.
18. Carlsson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer’s 
disease. J Alzheimers Dis. 2010;20(3):711-22.
19. Naderali EK, Ratcliffe SH, Dale MC. Obesity and Alzheimer's disease: a link 
between body weight and cognitive function in old age. Am J Alzheimers Dis 
Other Demen. 2009 Dec-2010 Jan;24(6):445-9.
20. Fratiglioni L, Paillard-Borg S, Winbald B. An active and socially integra-
ted lifestyle in late life might protect against dementia. Lancet Neurol. 2004 
Jun;3(6):343-53.
21. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis 
of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 
1999 Feb;66(2):137-47.
22. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of 
Memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003 
Fall;9(3):275-308.
23. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. 
Correlative memory deficits, Aß elevation, and Amyloid plaques in transgenic 
mice. Science. 1996 Oct 4;274(5284):99-102.
a series of secondary downstream events, such as the accu-
mulation of tau and inflammatory processes that cause neu-
ronal destruction.57 Targeting NPs after a certain point would 
no longer be beneficial, as other processes become the main 
propagating factors of the disease. This indicates that perhaps 
the targeting of NPs much earlier on and in larger doses may 
be key to anti-amyloid therapies. As such, the way forward in 
the treatment of AD seems to be the switch from trying to cure 
AD to instead attempting to prevent it. 
The International Journal of Medical StudentsInt J Med Students   •   2014  Mar-Jun  |  Vol  2  |  Issue 2 63
Review
24. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et 
al. Abeta oligomer-induced aberrations in synapse composition, shape, and 
density provide a molecular basis for loss of connectivity in Alzheimer's 
disease. J Neurosci. 2007 Jan 24;27(4):796-807.
25. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. 
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central ner-
vous system neurotoxins. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-
53.
26. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists fina-
lly shake hands?. Trends Neurosci. 2002 Jan;25(1):22-6.
27. Trojanowski JQ, Lee VMY. Rous-Whipple Award Lecture. The Alzheimer's 
brain: finding out what's broken tells us how to fix it. Am J Pathol. 2005 
Nov;167(5):1183-8.
28. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic 
plaques and tangles to the development and evolution of AD. Neurology. 
2004 Jun 8;62(11):1984-9.
29. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Data-
base Syst Rev. 2006 Jan 25;(1):CD005593.
30. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term 
donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): ran-
domized double-blind trial. Lancet. 2004 Jun 26;363(9427):2105-15.
31. Cummings J, Froelich L, Black SE, Bakchine S, Belleli G, Molinuevo JL, 
et al. Randomized, double-blind, parallel-group, 48-week study for efficacy 
and safety of a higher-dose rivastigmine patch (15 vs. 10cm2) in Alzheimer’s 
disease. Dement Geriatr Cogn Disord. 2012;33(5):341-53.
32. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobiue HJ, et al. Me-
mantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 Apr 
3;348(14):1333-41.
33. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CK. Effi-
cacy of Memantine on behavioural and psychological symptoms related to 
dementia: a systematic meta-analysis. Ann Pharmacother. 2008 Jan;42(1):32-
8.
34. Zec RF, Burkett NR. Non-pharmacological and pharmacological treatment 
of the cognitive and behavioural symptoms of Alzheimer disease. NeuroRe-
habilitation. 2008;23(5):425-38.
35. Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, et al. Cognitive 
effects of atypical antipsychotic medications in patients with Alzheimer’s 
disease: outcomes from CATIE-AD. Am J Psychiatry. 2011 Aug;168(8):831-9.
36. Van Marum RJ. Current and future therapy in Alzheimer’s disease. Fun-
dam Clin Pharmacol. 2008 Jun;22(3):265-74.
37. Weksler ME. The immunotherapy of Alzheimer’s disease. Immun Ageing. 
2004 Nov 12;1(1):2.
38. Ghosh AK, Brindisi M, Tang J. Developing ß-secretase inhibitors for treat-
ment of Alzheimer’s disease. J Neurochem. 2012 Jan;120 Suppl 1:71-83. 
39. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is 
the major beta-secretase for generation of Abeta peptides by neurons. Nat 
Neurosci. 2001 Mar;4(3):233-4.
40. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. 
Robust central reduction of amyloid-ß in humans with orally available, 
non-peptidic ß-secretase inhibitor. J Neurosci. 2011 Nov 16;31(46):16507-16.
41. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp B, et al. Bace1 modula-
tes myelination in the central and peripheral nervous system. Nat Neurosci. 
2006 Dec;9(12):1520-5.
42. Velanac V, Unterbarnscheidt T, Hinrichs W, Gummert MN, Fischer TM, 
Rossner MJ, et al. Bace1 processing of NRG1 type III produces a myelin-indu-
cing signal but is not essential for the stimulation of myelination. Glia. 2012 
Feb;60(2):203-17.
43. Zhao G, Liu Z, Ilagan MX, Kopan R. Gamma-secretase composed of PS1/
Pen2Aph1a can cleave notch and amyloid precursor protein in the absence 
of nicastrin. J Neurosci. 2010 Feb 3;30(5):1648-56.
44. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, et al. Prese-
nilins are required for gamma-secretase cleavage of beta-APP and transmem-
brane cleavage of Notch-1. Nat Cell Biol. 2000 Jul;2(7):463-5.
45. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert 
W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid 
precursor protein. Nature. 1998 Jan 22;391(6665):387-90.
46. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et 
al. A presenilin-1-dependent gamma-secretase-like protease mediates relea-
se of Notch intracellular domain. Nature. 1999 Apr 8;398(6727):518-22.
47. De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and ?-secretase: structu-
re, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med. 
2012 Jan;2(1):a006304.
48. Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, et al. Gleevec inhibits be-
ta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A. 2003 
Oct 14;100(21):12444-9.
49. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. 
Safety, tolerability, and changes in amyloid beta concentrations after admi-
nistration of gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 
2005 May-Jun;28(3):126-32.
50. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat 
(LY450139), a functional gamma-secretase inhibitor, for the treatment of Al-
zheimer’s disease. Expert Opin Pharmacother. 2009 Jul;10(10):1657-64.
51. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. 
Phase 2 safety trial targeting amyloid beta production with a gamma-secreta-
se inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug;65(8):1031-8.
52. Marder K. Tarenflurbil in patients with mild Alzheimer’s disease. Curr 
Neurol Neurosci Rep. 2010 Sep;10(5):336-7.
53. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, et al. Multi-
center, randomized, double-blind, placebo-controlled, single-ascending dose 
study of the oral ?-secretase inhibitor BMS-708163 (Avagacestat): tolerability 
profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin 
Ther. 2012 Mar;34(3):654-67.
54. Coric v, vanDyck CH, Salloway S, Andreasen N, Brody M, Richter RW, 
et al. Safety and tolerability of the ?-secretase inhibitor avagescat in a 
phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 
Nov;69(11):1430-40.
55. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et 
al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: fo-
llow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 Jul 
19;372(9634):216-23.
56. Lippa CF, Nee LE, Mori H, St George-Hyslop P. Abeta-42 deposition precedes 
other changes in PS-1 Alzheimer's disease. Lancet. 1998 Oct 3;352(9134):1117-
8.
57. St George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Al-
zheimer’s disease?. Lancet. 2008 Jul 19;372(9634):180-2.
Acknowledgments
I would like to thank Prof T. Francis, PhD, Professor of Neurochemistry, Director of Brains for Dementia Research, KCL, for his guidance in 
this article. 
Conflict of Interest Statement & Funding
The authors have no funding, financial relationships or conflicts of interest to disclose.
Author Contributions
Conception and design the work/idea: EC. Write the manuscript: EC. 
Cite as: 
Chou E. Alzheimer’s Disease: Current and Future Treatments. A Review. Int J Med Students. 2014 Mar-Jun;2(2):56-63.
